C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 19/00 (2006.01) C07K 14/52 (2006.01) C07K 14/55 (2006.01) C07K 14/705 (2006.01) C07K 14/73 (2006.01)
Patent
CA 2320403
Disclosed are methods for the genetic construction and expression of antibody- based fusion proteins with enhanced circulating half-lives. The fusion proteins of the present invention lack the ability to bind to immunoglobulin Fc receptors, either as a consequence of the antibody isotype used for fusion protein construction, or through directed mutagenesis of antibody isotypes that normally bind Fc receptors. The fusion proteins of the present invention may also contain a functional domain capable of binding an immunoglobulin protection receptor.
On décrit des procédés de construction génétique et d'expression de protéines hybrides à base d'anticorps ayant une demi-vie circulante améliorée. Les protéines hybrides de l'invention sont incapables de se lier aux récepteurs pour le fragment Fc des immunoglobulines, soit en conséquence de l'utilisation de l'isotype des anticorps pour construire la protéine hybride, soit par mutagenèse dirigée des isotypes des anticorps qui se lient normalement aux récepteurs pour le fragment Fc. Les protéines hybrides de l'invention peuvent également contenir un domaine fonctionnel capable de lier un récepteur de protection des immunoglobulines.
Gillies Stephen D.
Lan Yan
Lo Kin-Ming
Wesolowski John
Lexigen Pharmaceuticals Corporation
Merck Patent Gmbh
Smart & Biggar
LandOfFree
Enhancing the circulating half-life of antibody-based fusion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancing the circulating half-life of antibody-based fusion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancing the circulating half-life of antibody-based fusion... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1642378